高剂量与低剂量瑞舒伐他汀对急性冠脉综合征患者血清脑钠肽、炎性因子及血脂水平的影响观察
| 作者: |
1廖育山,
2洪长江,
1李志雄
1 南海经济开发区人民医院心血管内科，广东 佛山 528237 2 广州军区总医院心血管内科，广州 510010 |
| 通讯: |
廖育山
Email: lia073040yu@sina.com |
| DOI: | 10.3978/j.issn.2095-6959.2016.09.028 |
摘要
目的：探究高剂量与低剂量瑞舒伐他汀对急性冠脉综合征患者血清脑钠肽(brain natriuretic peptide，BNP)、超敏C反应蛋白(hs-CRP)及白细胞介素-6(IL-6)水平及血脂水平的影响。方法：选取我院2014年6月至2015年6月收治的急性冠脉综合征患者共71例作为研究对象，按照入院时间顺序随机分为低剂量组(N=35)与高剂量组(N=36)，低剂量组服用瑞舒伐他汀10 mg/d，高剂量组服用瑞舒伐他汀20 mg/d，比较两组患者治疗前后血清中BNP、hs-CRP及IL-6水平及血脂变化及不良反应发生率。结果：治疗前两组患者血清BNP、hs-CRP、IL-6及血脂相关指标无明显差异，P>0.05。治疗后，两组患者血清BNP、hs-CRP、IL-6、TC、LDL-C均较治疗前降低，HDL较治疗前升高，P<0.05。治疗后，高剂量组血清BNP、hs-CRP、IL-6、TC、LDL-C明显低于低剂量组，HDL高于低剂量组，P<0.05。AMI及UA患者治疗前血清BNP、hs-CRP、IL-6无明显统计学差异，P>0.05。治疗后，高剂量组AMI及UA患者血清BNP、hs-CRP及IL-6明显低于低剂量组，P<0.05。两组患者不良反应发生率无明显差异，P>0.05。结论：高剂量(20 mg)瑞舒伐他汀可以有效降低血清BNP、hs-CRP、IL-6及血脂水平，降低急性冠脉综合征(acute coronary syndrome，ACS)患者体内炎症反应水平，安全、无明显不良反应，值得临床推广。
关键词：
剂量
瑞舒伐他汀
急性冠脉综合征
血清脑钠肽
超敏C反应蛋白
白细胞介素-6
脂代谢
The effects of high dose and low dose of rosuvastatin on serum BNP, inflammatory factor and blood lipid levels in patients with acute coronary syndrome
CorrespondingAuthor: LIAO Yushan Email: lia073040yu@sina.com
DOI: 10.3978/j.issn.2095-6959.2016.09.028
Abstract
Objective: To explore the effect of different high dose and low dose of rosuvastatin on serum brain natriuretic peptide (BNP), high sensitive C reactive protein (hs-CRP), interleukin 6 (IL-6) and blood lipid levels in patients with acute coronary syndrome. Methods: A total of 71 patients with acute coronary syndrome admitted into our hospital from June 2014 to June 2015 were selected as the study subjects, and all patients were randomly divided into low dose group (N=35) and high dose group (N=36) according to the time sequence of admission. The low dose group was treated with 10 mg/d rosuvastatin, while the high dose group 20 mg/d rosuvastatin. The changes of serum BNP, hs-CRP, IL-6, blood lipid levels and the incidence of adverse reaction were compared between the two groups before and after treatment. Results: Before treatment, there were no significant differences in serum BNP, hs-CRP, IL-6 and serum lipid levels between the two groups, P>0.05. After treatment, the serum BNP, hs-CRP, IL-6, TC, LDL-C in two groups were lower than before treatment, and HDL was higher than before treatment, P<0.05. After treatment, the serum BNP, hs-CRP, IL-6, TC, LDL-C in high dose group were significantly lower than those in low dose group, while HDL higher than those in low dose group, P<0.05. Before treatment, The serum BNP, hs-CRP, IL-6 had no significant statistical differences between low dose group and high dose group of AMI and UA patients, P>0.05. After treatment, the serum levels of BNP, hs-CRP and IL-6 in high dose group with AMI and UA were significantly lower than those in the low dose group, P<0.05. There was no significant difference in the incidence of adverse reactions between the two groups, P>0.05. Conclusion: High dose (20 mg) rosuvastatin can effectively reduce the serum BNP, hsCRP, IL-6 and lipid levels, and reduce the inflammatory reaction in patients with ACS, which is safety and no obvious adverse reaction. It is worthy of clinical promotion.